Phase <scp>II open‐label</scp> multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor <scp>DNA</scp>: <scp>Liquid‐Lung‐A</scp>
Thoracic cancer